Compare ADMA Biologics Inc (ADMA) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Huntington Bancshares Incorporated — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Huntington Bancshares Incorporated trades at $17.46 (market cap $36.50B). The key difference: Huntington Bancshares Incorporated is far larger — about 17.1× ADMA Biologics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.44% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HBAN | |
|---|---|---|
Market Cap | $2.13B | $36.50B |
Sector | Health | Financials |
52-Week High | $20.38 | $19.27 |
52-Week Low | $7.60 | $15.02 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Huntington Bancshares (HBAN) trades at $18.01, up 0.84% with bullish technical indicators and strong analyst support. The stock shows solid fundamentals with Q1 2026 EPS beating expectations at $0.26 vs. $0.23, revenue growth to $8.13B in 2025, and a reasonable P/E of 13.77. Recent news highlights successful Texas expansion and banking tech awards, while cash flow trends show consistent operational strength.
HBAN presents a compelling buy case with 51% analyst buy ratings and a $19.90 price target offering 10% upside. Key opportunities include M&A synergies and digital banking growth, though risks remain from integration challenges and competitive pressures in regional banking markets. The stock's current valuation and growth trajectory support a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
